FinancialContent is the trusted provider of stock market information to the media industry.
February 23, 2012 at 13:08 PM EST
FDA Advisory Committee Recommends Approval For Qnexa

A Food and Drug Administration advisory committee recommended approval for Vivus Inc.'s (Nasdaq: VVUS) obesity treatment Qnexa. The news also lifted rival Orexigen Therapeutics Inc. (Nasdaq: OREX). Shares of Vivus leaped $9.22 to $19.77 while Orexigen stock climbed 55 cents to $3.76.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More